|Articles|May 1, 1999

May 1999
Volume 5
Issue 5

Overview of Platelet Glycoprotein IIb/IIIa Receptor Antagonist Treatment in the Management of Coronary Interventions and Acute Ischemic Coronary Syndromes

Author(s)Olga Bessmertny, BS, Judy W.M. Cheng, PharmD, BCPS

Download PDF: Overview of Platelet Glycoprotein IIb/IIIa Receptor Antagonist Treatment in the Management of Coronary Interventions and Acute Ischemic Coronary Syndromes

Articles in this issue

about 27 years ago

Article

Relationship between Primary Payer and Use of Proactive Immunization Practices: A National Survey

about 27 years ago

Article

Polypharmacy Management in Medicare Managed Care: Changes in Prescribing by Primary Care Physicians Resulting from a Program Promoting Medication Reviews

about 27 years ago

Article

Course and Cost of Treatment for Depression with Fluoxetine, Paroxetine, and Sertraline

about 27 years ago

Article

Project LEAP of New Jersey: Lower Extremity Amputation Prevention in Persons with Type 2 Diabetes

about 27 years ago

Article

Quality of Care for Chronic Illness in Primary Care: Opportunities for Improvement in Process and Outcome Measures

about 27 years ago

Article

Assessment of Patient Satisfaction with a Formulary Switch from Omeprazole to Lansoprazole in Gastroesophageal Reflux Disease Maintenance Therapy

about 27 years ago

Article

Benign Prostatic Hyperplasia: An Overview for Pharmacists

about 27 years ago

Article

Correspondence regarding, "How Should Managed Care Treat Onychomycosis?"

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Overview of Platelet Glycoprotein IIb/IIIa Receptor Antagonist Treatment in the Management of Coronary Interventions and Acute Ischemic Coronary Syndromes

Articles in this issue

Related Content

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

Trending on AJMC

How Hospital Specialty Pharmacies Are Closing the Pharmacy Desert Gap

Targeting Oxidative Stress Could Fill a Gap in the Vitiligo Treatment Toolbox

Patients on GLP-1s Increasingly Carry Diagnoses for New Indications

5 FAQs: Ebola Outbreaks and the Challenge of Public Trust

Tisagenlecleucel Yields Promising Disease-Free Survival in High-Risk Pediatric ALL: Shannon L. Maude, MD, PhD